BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8402735)

  • 1. A protein fraction from aged garlic extract enhances cytotoxicity and proliferation of human lymphocytes mediated by interleukin-2 and concanavalin A.
    Morioka N; Sze LL; Morton DL; Irie RF
    Cancer Immunol Immunother; 1993 Oct; 37(5):316-22. PubMed ID: 8402735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferation and cytotoxicity of lectin-induced lymphokine-activated killer (LILAK) cells.
    Shimizu Y; Kuroki T; Shiomi S; Kobayashi K; Monna T
    J Gastroenterol Hepatol; 1991; 6(5):485-90. PubMed ID: 1657242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.
    Rabinowich H; Sedlmayr P; Herberman RB; Whiteside TL
    Cell Immunol; 1991 Jul; 135(2):454-70. PubMed ID: 1709827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Swainsonine, an inhibitor of glycoprotein processing, enhances cytotoxicity of large granular lymphocytes.
    Yagita M; Saksela E
    Scand J Immunol; 1990 Mar; 31(3):275-82. PubMed ID: 2108487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro.
    Helfand SC; Soergel SA; Modiano JF; Hank JA; Sondel PM
    Cancer Biother; 1994; 9(3):237-44. PubMed ID: 7820185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulatory effects of garlic extracts on proliferation of T-lymphocytes in vitro stimulated with concanavalin A.
    Colić M; Vucević D; Kilibarda V; Radicević N; Savić M
    Phytomedicine; 2002 Mar; 9(2):117-24. PubMed ID: 11995944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism.
    Rook AH; Hooks JJ; Quinnan GV; Lane HC; Manischewitz JF; Macher AM; Masur H; Fauci AS; Djeu JY
    J Immunol; 1985 Mar; 134(3):1503-7. PubMed ID: 3918102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y; Zighelboim J; Berek JS; Bonavida B
    Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer.
    Pisani RJ; Krco CJ; Wold LE; McKean DJ
    Am J Clin Pathol; 1989 Oct; 92(4):435-46. PubMed ID: 2552792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limiting dilution analysis (LDA) of cells responding to recombinant interleukin-2 without previous stimulation: evidence that all responding cells are lymphokine-activated potent effectors.
    Vie H; Bonneville M; Sondermeyer P; Moreau JF; Soulillou JP
    Immunology; 1986 Mar; 57(3):351-7. PubMed ID: 3082744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
    Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
    J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adrenocorticotropic hormone controls Concanavalin A activation of rat lymphocytes by modulating IL-2 production.
    Wermerskirchen AS; LaTocha DH; Clarke BL
    Life Sci; 2000 Sep; 67(18):2177-87. PubMed ID: 11045599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxicity.
    Baxevanis CN; Voutsas IF; Soler MH; Gritzapis AD; Tsitsilonis OE; Stoeva S; Voelter W; Arsenis P; Papamichail M
    Immunopharmacol Immunotoxicol; 1998 Aug; 20(3):355-72. PubMed ID: 9736441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 2 (IL 2) up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation.
    Harel-Bellan A; Bertoglio J; Quillet A; Marchiol C; Wakasugi H; Mishall Z; Fradelizi D
    J Immunol; 1986 Apr; 136(7):2463-9. PubMed ID: 3005412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
    Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
    J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence of concanavalin-A(Con-A)-like molecules on natural-killer (NK)-sensitive target cells: their possible role in swainsonine-augmented human NK cytotoxicity.
    Yagita M; Noda I; Maehara M; Fujieda S; Inoue Y; Hoshino T; Saksela E
    Int J Cancer; 1992 Oct; 52(4):664-72. PubMed ID: 1399150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.
    Weil-Hillman G; Voss SD; Fisch P; Schell K; Hank JA; Sosman JA; Sugamura K; Sondel PM
    Cancer Res; 1990 May; 50(9):2683-91. PubMed ID: 1691679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.